

Ho Yeong Lim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2071929/ho-yeong-lim-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

6,919
citations

32
h-index

81
g-index

202
ext. papers

10,427
ext. citations

4.9
avg, IF

5.79
L-index

#	Paper	IF	Citations
193	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.. <i>Genome Medicine</i> , 2022 , 14, 1	14.4	2
192	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 433-433	2.2	1
191	Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 436-436	2.2	0
190	Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 415-415	2.2	0
189	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.. <i>Liver Cancer</i> , 2022 , 11, 38-47	9.1	5
188	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	1
187	Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.. <i>Journal of Hepatology</i> , 2021 ,	13.4	39
186	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2021 ,	7.9	5
185	Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. <i>Advances in Therapy</i> , 2021 , 38, 2472-2490	4.1	6
184	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021 , 10, 275-284	9.1	9
183	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16122-e16122	2.2	
182	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021 , 125, 200-208	8.7	5
181	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4700-4709	12.9	17
180	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4072-4072	2.2	1
179	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021 , 74, 350-359	13.4	51
178	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1593-1603	7.4	9
177	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021 , 127, 865-874	6.4	8

176	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021 , 99, 365-372	3.6	2
175	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021 , 12, 460-466	4.5	2
174	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. <i>Journal of Cancer</i> , 2021 , 12, 5681-5686	4.5	
173	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 267-267	2.2	107
172	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 268-268	2.2	5
171	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 318-318	2.2	
170	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 991-1001	21.7	37
169	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , 2021 , 41, 795-808	3.2	0
168	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , 2021 , 127, 4585-4593	6.4	2
167	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	
166	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2991-3001	2.2	51
165	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. <i>In Vivo</i> , 2021 , 35, 499-505	2.3	0
164	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921992992	5.4	11
163	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021 , 10, 451-460	9.1	3
162	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920965842	5.4	3
161	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 382, 1894-1905	59.2	1496
160	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.. <i>Translational Cancer Research</i> , 2020 , 9, 3367-3374	0.3	4
159	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020 , 40, 2544-2552	7.9	17

158	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020 , 216, 152820	3.4	2
157	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020 , 2020, 4659062	4.5	2
156	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020 , 12, 17	14.4	8
155	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020 , 15, 185-192	5	1
154	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020 , 122, 1630-1637	8.7	190
153	Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4508-4508	2.2	60
152	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4596-4596	2.2	3
151	Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16680-e16680	2.2	3
150	Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 476-476	2.2	26
149	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 526-526	2.2	3
148	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 542-542	2.2	2
147	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 549-549	2.2	1
146	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 550-550	2.2	2
145	A clinical scoring system for survival prediction in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 436-436	2.2	
144	Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 446-454	5.2	2
143	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). <i>European Journal of Cancer</i> , 2020 , 127, 183-190	7.5	7
142	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 193-202	2.2	600
141	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920926796	5.4	5

140	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1059-1067	5.9	1
139	Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?. <i>Cancers</i> , 2020 , 12,	6.6	3
138	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020 , 5,	6	21
137	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , 2020 , 15, 203-209	5	
136	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019 , 8, 6986-6994	4.8	17
135	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019 , 12, 597-601	4.9	5
134	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 282-296	21.7	704
133	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019 , 10, 1611-1615	4.5	4
132	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019 , 10, 3140-3144	4.5	3
131	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2019 , 51, 510-518	5.2	25
130	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019 , 9, 1388-1405	24.4	78
129	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (≥ 5 Years) With Gastric Cancer. <i>Anticancer Research</i> , 2019 , 39, 5811-5820	2.3	4
128	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. <i>Scientific Reports</i> , 2019 , 9, 15365	4.9	34
127	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3104-3104	2.2	1
126	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4073-4073	2.2	6
125	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4534-4534	2.2	1
124	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 4508-4515	3	2
123	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 1128-1134	5.7	7

122	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019 , 51, 876-885	5.2	5
121	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 213-213	2.2	
120	Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 355-355	2.2	
119	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3023-3023	2.2	1
118	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs.. <i>Translational Cancer Research</i> , 2019 , 8, 2107-2112	0.3	
117	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019 , 10, 6185-6190	4.5	3
116	An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019 , 24, 747-e218	5.7	41
115	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019 , 14, e0210730	3.7	32
114	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019 , 37, 567-572	4.3	30
113	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 501-508	3.5	5
112	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019 , 12, 225-231	4.4	4
111	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 140-146	3.8	11
110	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 165-169	3.8	44
109	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018 , 11, 353-357	4.9	6
108	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 4650-4661	12.9	38
107	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018 , 9, 1791-1796	4.5	5
106	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018 , 129, 306-312	5.3	11
105	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 69	22.4	20

104	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018 , 24, 1449-1458	50.5	577
103	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018 , 9, 2910-2915	4.5	5
102	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4003-4003	2.2	62
101	Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4078-4078	2.2	2
100	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4088-4088	2.2	6
99	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14501-e14501	2.2	1
98	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , 2018 , 33, 383-390	2.5	7
97	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 175-182	5.2	8
96	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 488-494	5.2	20
95	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24234-e24234	2.2	
94	Detection of targetable fusions using FusionPlex in oncology patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24238-e24238	2.2	
93	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. <i>Translational Oncology</i> , 2018 , 11, 37-42	4.9	22
92	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018 , 18, 1103	4.8	15
91	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018 , 18, 348-355	3.2	8
90	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018 , 9, 3394-3399	4.5	4
89	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. <i>Investigational New Drugs</i> , 2018 , 36, 1072-1084	4.3	24
88	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 61-67	1.9	14
87	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , 2017 , 8, 170-175	3.6	26

86	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 782-790	4.3	17
85	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017 , 10, 469-475	4.9	21
84	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 191-200	3.7	3
83	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017 , 17, 211	4.8	21
82	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. <i>Journal of Cancer</i> , 2017 , 8, 730-736	4.5	1
81	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017 , 8, 1395-1399	4.5	17
80	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2809-2815	4.5	10
79	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. <i>Journal of Cancer</i> , 2017 , 8, 2713-2719	4.5	11
78	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	18
77	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017 , 8, 11094-11104	3.3	15
76	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017 , 8, 77415-77423	3.3	55
75	A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. <i>BMC Urology</i> , 2017 , 17, 63	2.2	5
74	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017 , 22, 1169-1177	5.7	10
73	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 27-31	1.6	13
72	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15610-e15610	2.2	1
71	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017 , 8, 3237-3245	3.3	13
70	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center experiences. <i>Oncotarget</i> , 2017 , 8, 42478-42486	3.3	16
69	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017 , 8, 73974-73980	3.3	3

68	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017 , 8, 105727-105734	12
67	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 96656-96667	3.3 17
66	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14622-e14622	2.2
65	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15686-e15686	2.2
64	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016 , 16, 46	2.2 13
63	Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery. <i>Tumori</i> , 2016 , 102, 114-21	1.7 8
62	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 64, 774-84	11.2 58
61	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1231-7	4.9 10
60	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 76-81	3.3 8
59	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2508-2508	2.2 15
58	Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4072-4072	2.2 2
57	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , 2016 , 7, 19610-9	3.3 10
56	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016 , 7, 24088-96	3.3 9
55	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016 , 34, 34-44	2.5 9
54	Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. <i>Cancer Research and Treatment</i> , 2016 , 48, 1243-1252	5.2 17
53	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15628-e15628	2.2
52	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4091-4091	2.2
51	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15153-e15153	2.2

50	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016 , 7, 1044-8	4.5	13
49	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016 , 48, 553-60	5.2	13
48	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016 , 16, 105-10	3.2	26
47	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016 , 7, 43492-43503	3.3	37
46	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , 2016 , 16, 120	4.8	31
45	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3130-41	2.2	271
44	Aggressive Intra-segmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. <i>Radiology</i> , 2015 , 276, 274-85	20.5	80
43	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. <i>Journal of Hepatology</i> , 2015 , 63, 896-904	13.4	32
42	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015 , 15, 530	4.8	15
41	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2015 , 117, 171-7	5.3	29
40	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015 , 62, 1112-21	13.4	42
39	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015 , 8, 288-94	4.9	7
38	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015 , 15, 747	4.8	6
37	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015 , 6, 40360-9	2.3	77
36	Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015 , 30, e382-6	2.8	19
35	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015 , 6, 28211-22	3.3	48
34	Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2015 , 47, 343-61	5.2	49
33	Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 256-60	2.8	13

32	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015 , 8, 40-6	4.9	14
31	Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 72-7	5.2	14
30	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2522-2522	2.2	1
29	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015 , 6, 24320-32	3.3	31
28	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015 , 6, 25619-30	3.3	42
27	The NEXT-1 (Next generation pERsonalized tX with mULTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015 , 6, 33358-68	3.3	21
26	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015 , 6, 40026-35	3.3	12
25	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015 , 6, 39028-35	3.3	46
24	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4049-4049	2.2	2
23	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3576-3576	2.2	
22	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22241-e22241	2.2	
21	Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014 , 50, 2822-30	7.5	52
20	Prognostic Value of Volume-Based Metabolic Parameters Measured by (18)F-FDG PET/CT of Pancreatic Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , 2014 , 48, 180-6	1.9	27
19	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. <i>European Journal of Cancer</i> , 2014 , 50, 746-52	7.5	17
18	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014 , 4, 7592	4.9	21
17	Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2527-36	6.1	26
16	A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 5976-85	12.9	75
15	Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 57-67	27.4	427

14	A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4151-TPS4151	2.2	6
13	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 172-172	2.2	21
12	Clinical features and treatment of collecting duct carcinoma of the kidney from the Korean cancer study group genitourinary and gynecology cancer committee. <i>Cancer Research and Treatment</i> , 2014 , 46, 141-7	5.2	11
11	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4008-4008	2.2	
10	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. <i>Anticancer Research</i> , 2014 , 34, 6585-91	2.3	2
9	Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3608-3608	2.2	1
8	Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naïve RCC (COMPARZ).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 366-366	2.2	5
7	Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15573-e15573	2.2	
6	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15613-e15613	2.2	
5	Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy: A subanalysis of REACT.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15064-e15064	2.2	1
4	Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14617-e14617	2.2	
3	A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13044-e13044	2.2	
2	Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer. <i>Tumori</i> , 2010 , 96, 568-576	1.7	7
1	Identification of Leukemia Surface Proteins Using a Proteomic Technique. <i>The Korean Journal of Hematology</i> , 2006 , 41, 272		